Clinical trial · Observational
Intestinal Microbiome After Gastrectomy
Surgical Gastric Cancer Treatment: Influence on Intestinal Microbiome
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The gastric barrier plays a major role in the maintanance of the distal intestinal microbiome composition. It has been shown before that the use of gastric acid suppression medication, such as proton pump inhibitors, are associated with distinctive alterations of the intestinal microbiome. Foremost, the invasion of predominantly oral bacteria, like Veillonella and Streptococcus species, were a resurring finding in previous reports. Gastric cancer treatment includes the total or subtotal resection of the stomach which can influence the gastric acid production. However, the influence by alterations in gastric milieu after this treatment on the composition of the intestinal microbiome is not well studied. Therefore, the intestinal microbiome of patients after total or subtotal gastrectomy and its influence on intestinal inflammation and gut permeability will be studied.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (4)
- label
- Test group
- description
- Patients who underwent total or subtotal gastrectomy for the treatment of gastric cancer
- label
- Control group 1
- description
- Patients who underwent endoscopic mucosal resection/submucosal dissection for the treatment of gastric cancer
- label
- Control group 2
- description
- In-house relatives of Test group and Control group 1 participants
- label
- Control group 3
- description
- Patients with long-term history of proton pump inhibitor usage
Primary outcomes (1)
- measure
- Intestinal microbiome composition
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * age 18 years and above * history of radical removal of gastric cancer (Test group and Control group 1) or PPI (Control group 3) * informed consent Exclusion Criteria: * chemotherapy or radiotherapy 12 months prior to inclusion * gastric stump cancer * usage of antibiotics, pro- pre or synbiotics, H2-blocker 1 month prior to inclusion * PPI use (except for Control group 3) 1 month prior to inclusion * history of radical removal of gastric cancer (Control group 2-3) * history of gastrointestinal tract resections (other than gastric) * recurrence of gastric cancer * current non-gastric malignancies
References
Publications (1)
- DERIVEDHorvath A, Bausys A, Sabaliauskaite R, Stratilatovas E, Jarmalaite S, Schuetz B, Stiegler P, Bausys R, Stadlbauer V, Strupas K. Distal Gastrectomy with Billroth II Reconstruction is Associated with Oralization of Gut Microbiome and Intestinal Inflammation: A Proof-of-Concept Study. Ann Surg Oncol. 2021 Feb;28(2):1198-1208. doi: 10.1245/s10434-020-08678-1. Epub 2020 Jun 5. PMID 32504369